We measure our success in the value of human life.

FIT Biotech

FIT Biotech is an innovative medical biotechnology company engaged in the development and commercialisation of its proprietary Gene Transport Unit (GTU®) technology and GTU® product applications in DNA vaccination as well as in immuno- and gene therapies.

News and Events

Press Release 19.7.2010 / July-19-2010

Phase II Data From FIT Biotech’s HIV Immunotherapy Show Reduction in Viral Load and Increase in CD4 Cell Count
Read more

Lehdistötiedote 19.7.2010 / July-19-2010

Lupaavia tuloksia HIV-positiivisten hoitoon uuden DNA-rokoteteknologian ansiosta
Read more

Press Release 30.6.2010 / June-30-2010

EU-rahoitusta suositeltu FIT Biotechin tuberkuloosirokotehankkeelle
Read more

Press Release 29.3.2010 / March-29-2010

Finnish vaccine technology plays key role in development of a new tuberculosis vaccine
Read more

Lehdistötiedote 29.3.2010 / March-29-2010

Suomalainen rokoteteknologia avainasemassa tehokkaamman tuberkuloosirokotteen kehitystyössä
Lue lisää

Research and Development

Research & Development

FIT Biotech's most important R&D activity since the start of its operations has been the development of an HIV vaccine.

 

R&D Publications